ACC 2016: Recent Advances to Improve Outcomes for Patients with Dyslipidemia

http://academiccme.com/wp-content/uploads/2016/06/910620-125-x-125.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Meeting Reporter, Downloadable Transcript
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: June 8, 2016 - June 7, 2017

 

PROGRAM OVERVIEW

This Official Elsevier Medical Meeting Reporter will cover data presented at the American College of Cardiology 65th Annual Scientific Session and Expo held in Chicago, Illinois. The four expert faculty will communicate imperative information for clinical decision-making, as it relates to the comprehensive healthcare team, in both the initiation of treatment and effective communication of therapeutic options with the patient. Criteria for statin intolerance and familial hypercholesterolemia will be reviewed in order to ensure physicians are making informed decisions. At the conclusion of this program, learners should be able to create individualized treatment plans incorporating PCKS9 Inhibitors to both reduce risk and improve outcomes in their dyslipidemia patients.

 

TARGET AUDIENCE

Cardiologists, internists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.

 

EDUCATIONAL OBJECTIVES

  1. Review the diagnostic and patient assessment criteria for statin intolerance and familial hypercholesterolemia in patients with dyslipidemia.
  2. Examine clinical trial data of current and emergent PCSK9 inhibitors for the treatment of dyslipidemia.
  3. Formulate personalized treatment plans to incorporate PCSK9 inhibitors to reduce risk and improve outcomes for patients with dyslipidemia.


Registration



This activity has been supported by an independent educational grant from Amgen Inc.

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME
eocme acme logo